The protective effects of prostaglandin E1 on sinusoidal endothelial cells in xenogeneic pig liver perfusion.
The effects of prostaglandin E1 (PGE1) on hepatic sinusoidal endothelial cells (SEC) in the xenogeneic immunoreaction were investigated. Porcine livers were perfused with fresh human blood via the portal vein (PV) and the hepatic artery (HA) either with the administration of PGE1 (Group PG) or without PGE1 (Group C). The creatine kinase-BB component (CK-BB) in the perfusate was measured to assess SEC damage. SEC activation and complement activation were evaluated immunohistochemically by the expression of von Willebrand factor (vWF) and by the deposition of membrane attack complex (MAC), respectively. Xenoperfusion in Group C was discontinued between 4 and 6 hr due to the rapid elevation of HA pressures and the massive loss of perfusate. In Group PG, both PV and HA pressures were kept stable for up to 9 hr. In Group C, severe interlobular bleeding and diffuse extrasinusoidal hemorrhage were observed at 4 hr histologically, while in Group PG, the hepatic architecture was maintained without hemorrhage at 6 hr. MAC was markedly deposited on SEC and parenchymal cells at 3 hr in both groups. The amount of vWF, however, was expressed on SEC in large amounts at 1 hr in Group C, while small amounts were expressed at 1 hr in Group PG. In Group PG, CK-BB release was significantly lower than in Group C (P < 0.01). These results suggest that PGE1 suppressed SEC activation and protected the impairment of hepatic SEC during xenoperfusion without suppressing complement activation, resulting in the prolongation of xenogeneic liver perfusion.
Yagi
T
T
Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Kyoto, Sakyo-ku, 606-01, Japan.
Ikai
I
I
Terajima
H
H
Satoh
S
S
Kanazawa
A
A
Shinohara
H
H
Uesugi
T
T
Yoneyama
T
T
Gomi
T
T
Takahashi
R
R
Yamamoto
M
M
Inamoto
T
T
Yamaoka
Y
Y
D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D001646:Bile / Q000378:metabolism; D001769:Blood; D001794:Blood Pressure; D003167:Complement Activation; D015938:Complement Membrane Attack Complex / Q000032:analysis / Q000378:metabolism; D003402:Creatine Kinase / Q000032:analysis; D004727:Endothelium / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D006470:Hemorrhage; D006499:Hepatic Artery; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D007150:Immunohistochemistry; D007527:Isoenzymes; D008099:Liver / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology / Q000276:immunology; D010477:Perfusion; D011169:Portal Vein; D013552:Swine; D014183:Transplantation, Heterologous; D014841:von Willebrand Factor / Q000032:analysis / Q000378:metabolism
D015938:Complement Membrane Attack Complex; D007527:Isoenzymes; D014841:von Willebrand Factor; D006820:Hyaluronic Acid; D003402:Creatine Kinase; D000527:Alprostadil